Delta 9 Cannabis Inc. (TSX:DN) said it has appointed Dr David Kideckel as its executive vice president, Head of Strategy, Corporate Development & Capital Markets, a newly created position to lead the company’s next phase of growth expansion.
The company noted that Kideckel joins it after nearly 20 years of combined industry and capital markets experience, most recently serving as managing director, senior institutional equity research analyst at ATB Capital Markets.
His industry experience spans several senior healthcare executive roles including at Johnson & Johnson (NYSE:JNJ) Inc. and Alexion Pharmaceuticals (NASDAQ:ALXN) (acquired by AstraZeneca). Within Capital Markets, Kideckel was at the forefront of the cannabis industry and was the sole Bay Street analyst to cover GW Pharmaceuticals (acquired by Jazz Pharmaceuticals), and was known for his expert analyses and thought leadership in retail, LP’s, US & international strategy & partnerships, as well as cannabinoid-derived pharmaceuticals and biosynthesis.
READ: Delta 9 Cannabis 2Q revenue climbs 29% to C$16.8M as it continues to advance its retail and online sales strategy
“I am extremely pleased to welcome David to our team, propelling our capital markets strategy and reach, through his wealth of experience. David was one of the leading cannabis analysts and has an exceptional network of contacts with an in-depth knowledge of the cannabis industry and its subsectors. David’s appointment reflects our commitment to having best-in-class talent to advance the Company’s growth trajectory strategically and expeditiously,” said John Arbuthnot, CEO of Delta 9 in a statement.
“Of all the companies I have evaluated over the last several years, Delta 9 has incredible potential and I’m proud to join a seasoned team that is on the verge of steady and continuous growth within an explosive industry,” added Kideckel.
Delta 9 Cannabis. is a vertically integrated cannabis company focused on bringing the highest quality cannabis products to market. The company sells cannabis products through its wholesale and retail sales channels and sells its cannabis grow pods to other businesses.
The company's wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical and recreational cannabis and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9 owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand.
Contact the author at jon.hopkins@proactiveinvestors.com